AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview

 
• By Sarah Karlin-Smith

The confirmatory trial for the anticoagulant reversal agent raised safety and efficacy concerns from the agency.

exit painted on pavement.
A negative 21 November advisory committee recommendation could portend a marketing exit for Andexxa. (Shutterstock)

More from US Advisory Committees

More from Product Reviews